ロード中...
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment
PURPOSE: We assessed pulmonary toxicity of cyclin-dependent kinase (CDK)4/6 inhibitors by analyzing the publicly available FDA Adverse Event Reporting System (FAERS). METHODS: Reports of interstitial lung disease (ILD) were characterized in terms of demographic information, including daily dose, lat...
保存先:
| 出版年: | Breast Cancer Res Treat |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer US
2020
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7641870/ https://ncbi.nlm.nih.gov/pubmed/33150548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-06001-w |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|